|
Sep 19, 2023
|
Innoviva to Participate in the Cantor Global Healthcare Conference
|
|
|
Sep 18, 2023
|
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
|
|
|
Aug 25, 2023
|
Innoviva Appoints Stephen Basso as Chief Financial Officer
|
|
|
Aug 02, 2023
|
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
|
|
|
Jul 11, 2023
|
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
|
|
|
Jun 06, 2023
|
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
|
|
|
May 23, 2023
|
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
|
|
|
May 11, 2023
|
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
|
|
|
May 09, 2023
|
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
|
|
|
Apr 28, 2023
|
Innoviva Announces Retirement of Board Chairman
|
|